Theragenics To Report First Quarter 2012 Financial Results Thursday, May 10
Theragenics Corporation ® (NYSE: TGX) expects to release first quarter 2012 financial results before the market opens on May 10, 2012. Following this release, the Company will host a conference call at 11:00 a.m. Eastern.
To participate in the call, dial 877-407-4019 or 201-689-8337. The call is also being webcast and can be accessed via Theragenics’ website, www.theragenics.com. A replay will be available on the website for one month. A phone replay will be available until Midnight, May 17, 2012 by dialing 877-660-6853 or 201-612-7415, and entering the account # 372 and conference ID 393250.
Theragenics Corporation (NYSE: TGX) operates two business segments: its
surgical products business and its brachytherapy seed business. Its
surgical products business (
www.cpmedical.com,
www.galtmedical.com,
www.needletech.com)
manufactures and distributes wound closure, vascular access, and
specialty needle products. Wound closure products include sutures,
needles and other surgical products. Vascular access includes
introducers, guidewires and related products. Specialty needles include
coaxial, biopsy, spinal and disposable veress needles, access trocars,
and other needle based products. The surgical products segment serves a
number of markets and applications, including, among others,
interventional cardiology, interventional radiology, vascular surgery,
orthopedics, plastic surgery, dental surgery, urology, veterinary
medicine, pain management, endoscopy, and spinal surgery. Theragenics’
brachytherapy business manufactures, markets and distributes “seeds”
used primarily in the minimally invasive treatment of localized prostate
cancer. The Company’s brachytherapy product line includes its
palladium-103 TheraSeed
® device (
www.theraseed.com)
and its iodine-125 devices.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
